{
    "Trade/Device Name(s)": [
        "Elecsys CA 125 II Assay",
        "Elecsys CA 125 II CalCheck"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K143534",
    "Predicate Device Reference 510(k) Number(s)": [
        "K972162",
        "K102086"
    ],
    "Regulatory Class": "II",
    "Product Code(s)": [
        "LTK",
        "JJX"
    ],
    "Summary Letter Date": "July 6, 2015",
    "Summary Letter Received Date": "July 7, 2015",
    "Submission Date": "August 6, 2015",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-associated antigen immunological test system"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "immunology"
    ],
    "Analyte(s)": [
        "CA 125",
        "OC 125 reactive determinants"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Li-heparin plasma",
        "K2-EDTA plasma",
        "K3-EDTA plasma",
        "Li-heparin plasma with separating gel"
    ],
    "Specimen Container(s)": [
        "Serum tube",
        "Li-heparin tube",
        "K2-EDTA tube",
        "K3-EDTA tube",
        "Li-heparin plasma tube with separating gel"
    ],
    "Instrument(s)/Platform(s)": [
        "cobas e 411 analyzer",
        "Elecsys and cobas e immunoassay analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescent immunoassay (ECLIA)",
        "Sandwich immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Calibration verification"
    ],
    "Submission Type(s)": [
        "Assay",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys CA 125 II Assay and Elecsys CA 125 II CalCheck for quantitative detection of CA 125 in human serum and plasma on cobas e 411 analyzer.",
    "Indications for Use Summary": "The Elecsys CA 125 II Assay is an immunoassay for the quantitative determination of OC 125 reactive determinants in human serum and certain plasma types, aiding in the detection of residual or recurrent ovarian carcinoma and in monitoring disease progress or response to therapy.",
    "fda_folder": "Immunology"
}